A Phase 1 interventional study of BMS-986446 IV and BMS-986446 SC in Healthy Volunteer, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-01.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess drug levels, tolerability and absolute biological availability of single subcutaneous dose of BMS-986446 in healthy participants
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986446 IV · Drug: Acetaminophen · Drug: Loratadine
Drug: BMS-986446 SC · Drug: Acetaminophen · Drug: Loratadine
Specified dose on specified days was administered intravenously (IV).
Specified dose on specified days was administered subcutaneously (SC).
Specified dose on specified days
Specified dose on specified days
Geometric Mean Ratio (GMR) of Maximum Observed Serum Concentration (Cmax) of BMS-986446 Administered IV versus SC
Time frame: Up to approximately Day 85
GMR of Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of BMS-986446 Administered IV versus SC
Time frame: Up to approximately Day 85
GMR of Area Under the Serum Concentration-time Curve From Time Zero to 672 Hours (AUC(0-672)) of BMS-986446 Administered IV versus SC
Time frame: Up to approximately Day 85
Absolute Bioavailability (F) Estimated From GMR of AUC(INF) of BMS-986446 Administered as SC versus IV Infusion
Time frame: Up to approximately Day 85
Number of Participants With Adverse Events (AEs)
Time frame: Up to approximately Day 85
Number of Participants With Serious Adverse Events (SAEs)
Time frame: Up to approximately Day 85
Number of Participants With AEs Reported Related to BMS-986446
Time frame: Up to approximately Day 85
Number of Participants With Clinically Significant Vital Sign Abnormalities
Time frame: Up to approximately Day 85
Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG)
Time frame: Up to approximately Day 85
Number of Participants With Clinically Significant Physical Examination (PE) Abnormalities
Time frame: Up to approximately Day 85
Number of Participants With Suicidality as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to approximately Day 85
Number of Participants With Clinically Significant Laboratory Assessment Abnormalities
Time frame: Up to approximately Day 85
Cmax of BMS-986446
Time frame: Up to approximately Day 85
AUC(0-T) of BMS-986446
Time frame: Up to approximately Day 85
AUC(0-672) of BMS-986446
Time frame: Up to approximately Day 85
Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-986446
Time frame: Up to approximately Day 85
Time of Maximum Observed Serum Concentration (Tmax) of BMS-986446
Time frame: Up to approximately Day 85
Apparent Terminal Serum Half-life (T-HALF) of BMS-986446
Time frame: Up to approximately Day 85
Total Body Clearance in IV Infusion (CLT) of BMS-986446
Time frame: Up to approximately Day 85
Apparent Total Body Clearance in SC Administration (CLT/F) of BMS-986446
Time frame: Up to approximately Day 85
Volume of Distribution of Terminal Phase in IV Infusion (Vz) of BMS-986446
Time frame: Up to approximately Day 85
Apparent Volume of Distribution of Terminal Phase in SC Administration (Vz/F) of BMS-986446
Time frame: Up to approximately Day 85
Number of Participants With Anti-drug Antibody Development
Time frame: Up to approximately Day 85
Local Tolerance Evaluation SC Administration of BMS-986646 Assessed by Questionnaire
Participant-reported response will be obtained using questionnaires that assess for pain (using a Numeric Rating Scale), itching, burning, pressure, and soreness/tenderness at the site injection.
Time frame: Up to approximately Day 85
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.htm
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · www.bms.com
Ran from May 2025 to primary completion in Sep 2025, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moponetug